[go: up one dir, main page]

NO20030856L - Membranpenetrerende peptider og anvendelse av disse - Google Patents

Membranpenetrerende peptider og anvendelse av disse

Info

Publication number
NO20030856L
NO20030856L NO20030856A NO20030856A NO20030856L NO 20030856 L NO20030856 L NO 20030856L NO 20030856 A NO20030856 A NO 20030856A NO 20030856 A NO20030856 A NO 20030856A NO 20030856 L NO20030856 L NO 20030856L
Authority
NO
Norway
Prior art keywords
penetrating peptides
membrane penetrating
interest
vivo
cells
Prior art date
Application number
NO20030856A
Other languages
English (en)
Other versions
NO332050B1 (no
NO20030856D0 (no
Inventor
Yong Guo
Clarence C Morse
Zhengbin Yao
Jr George A Keesler
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0103110.3A external-priority patent/GB0103110D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20030856D0 publication Critical patent/NO20030856D0/no
Publication of NO20030856L publication Critical patent/NO20030856L/no
Publication of NO332050B1 publication Critical patent/NO332050B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NO20030856A 2000-08-25 2003-02-24 Fusjonsprotein for avlevering av et organisk molekyl inn i en celle NO332050B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
PCT/US2001/026421 WO2002018572A2 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof

Publications (3)

Publication Number Publication Date
NO20030856D0 NO20030856D0 (no) 2003-02-24
NO20030856L true NO20030856L (no) 2003-04-24
NO332050B1 NO332050B1 (no) 2012-06-11

Family

ID=26245698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030856A NO332050B1 (no) 2000-08-25 2003-02-24 Fusjonsprotein for avlevering av et organisk molekyl inn i en celle

Country Status (9)

Country Link
EP (1) EP1360311B1 (no)
AT (1) ATE391791T1 (no)
AU (1) AU8524901A (no)
CA (1) CA2420350C (no)
IL (1) IL154589A0 (no)
MX (1) MXPA03001622A (no)
NO (1) NO332050B1 (no)
NZ (1) NZ524386A (no)
WO (1) WO2002018572A2 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086927A1 (en) 1995-11-01 2003-05-08 University Of Southern California Expression of cyclin G1 in tumors
EP0973538B1 (en) 1997-04-10 2008-03-12 University of Southern California Modified proteins which bind extracellular matrix components
FR2781674B1 (fr) * 1998-07-31 2002-06-28 Inst Nat Sante Rech Med Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
WO2003062398A2 (en) * 2002-01-23 2003-07-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services NEW TUMOR SUPPRESSOR GENE, p28ING5
WO2003064609A2 (en) * 2002-01-29 2003-08-07 Aventis Pasteur, Ltd. Targeted immunogens
KR20030078115A (ko) * 2002-03-28 2003-10-08 (주)코아바이오텍 펩타이드 유전자 전달매체 및 이를 이용한 유전자 전달 방법
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
CA2552251A1 (en) * 2003-12-31 2005-07-21 Sanofi Pasteur, Inc. Targeted immunogens
EP1950294B1 (en) 2005-10-28 2012-01-18 Mitsubishi Tanabe Pharma Corporation Novel cell penetrating peptide
EP2172210A1 (en) * 2005-12-23 2010-04-07 Partnership&Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
WO2010117079A1 (ja) 2009-04-10 2010-10-14 東亞合成株式会社 神経分化誘導ペプチド及びその利用
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
US20120149053A1 (en) * 2009-07-29 2012-06-14 Toagosei Co. Ltd. Carrier peptide fragment and use thereof
WO2011013698A1 (ja) * 2009-07-29 2011-02-03 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
JP5858285B2 (ja) 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
WO2011052679A1 (ja) 2009-11-02 2011-05-05 東亞合成株式会社 細胞増殖促進ペプチド及びその利用
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
KR101671114B1 (ko) 2015-06-26 2016-10-31 충북대학교 산학협력단 Ｕｌｋ２로부터 유래된 핵 위치화 신호 펩타이드 및 이의 용도
CA3228169A1 (en) * 2021-08-06 2023-02-09 The Trustees Of The Univeristy Of Pennsylvania Compositions and methods for treatment and prevention of misfolded proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
AU7022998A (en) * 1997-04-28 1998-11-24 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
SE9801055D0 (sv) * 1998-03-25 1998-03-25 Inst Of Molecul & Cell Biology Use of growth hormone binding protein (GHBP)
WO2001038547A2 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001093836A2 (en) * 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes

Also Published As

Publication number Publication date
NO332050B1 (no) 2012-06-11
WO2002018572A2 (en) 2002-03-07
MXPA03001622A (es) 2004-09-06
EP1360311B1 (en) 2008-04-09
EP1360311A2 (en) 2003-11-12
ATE391791T1 (de) 2008-04-15
AU8524901A (en) 2002-03-13
IL154589A0 (en) 2003-09-17
CA2420350C (en) 2010-07-13
WO2002018572A3 (en) 2003-09-12
CA2420350A1 (en) 2002-03-07
NZ524386A (en) 2005-10-28
NO20030856D0 (no) 2003-02-24

Similar Documents

Publication Publication Date Title
NO20030856D0 (no) Membranpenetrerende peptider og anvendelse av disse
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60144145D1 (de) Subtilisin-variante
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
BR0312764A (pt) Cardiomiócitos funcionais originados de células-tronco embrionárias humanas
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
AR030741A1 (es) Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
NO20032286D0 (no) Anvendelse av CLyA-hemolysin for utskillelse av proteiner
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
NO20031860L (no) Kahalalid F
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
YU90301A (sh) Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
DE60327710D1 (de) Modifizierte zytokine für krebs therapie
SE0103765D0 (sv) New use
BR0316544A (pt) Compostos calcilìticos
DK1230261T3 (da) NY-ESO-1 Nonapeptidderivater og anvendelser af disse
SI1458853T1 (sl) Postopki donorsko specifiŽŤnega navzkriĹľnega ujemanja
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
SE0001530D0 (sv) A reporter protein
ATE348176T1 (de) Komplex aus peptid und mhc-peptid auf oberfläche von phagen
ATE466077T1 (de) Eine metacaspasen-klasse

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AVENTISUB LLC, US

MK1K Patent expired